Ozempic-Class Drugs Tied to Rare Smell and Taste Problems

Here’s how significant the risk is and when to see a doctor.

Goskova Tatiana/Shutterstock

A sudden loss of smell or a metallic taste in the mouth may be an underreported side effect of GLP-1 drugs, according to a recent study tracking more than 870,000 adults with Type 2 diabetes, the largest look yet at a possible link between the blockbuster weight-loss and diabetes medications and changes in smell and taste.

Researchers found that patients taking GLP-1 medications had a 48 percent higher relative risk of developing smell or taste problems over two years compared with patients taking other diabetes treatments.

In real-world terms, that meant 0.37 percent of GLP-1 users developed these issues, versus 0.22 percent of those on other diabetes drugs—an increase of roughly one additional case per 700 patients treated.

The medication class includes widely prescribed drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), though the study grouped all GLP-1 drugs together rather than analyzing them individually, a limitation the authors themselves flagged, since different drugs in the class vary molecularly and may not carry identical risks.

“This study is a powerful reminder of what highly successful therapies can impact within our health picture—beyond the usual scope of measurement,” Dr. Kyle Hoedebecke, a family medicine physician and clinical advisor at Alpas Wellness NOVA in Virginia who was not involved in the study, told The Epoch Times, pointing to the study’s “sheer size” of more than 438,000 matched participants as its core strength.

Key Findings

The study, published in JAMA Otolaryngology–Head & Neck Surgery, analyzed medical records of adults with Type 2 diabetes, with half receiving GLP-1 drugs and the other half receiving different diabetes treatments, matched for age and sex.

Smell problems were more affected than taste. GLP-1 users were 81 percent more likely to report smell disturbances and 52 percent more likely to report taste disturbances, though both remained rare in absolute terms.

The sensory issues included anosmia, or loss of smell, and parosmia, which causes smells to seem distorted. Taste disturbances involved parageusia, or a distorted sense of taste.

Smell and taste are more than a matter of enjoying food; they’re also considered early indicators of overall health and can, in some cases, signal more serious neurological conditions like Parkinson’s or Alzheimer’s disease.

GLP-1 receptors are highly concentrated in the brain regions that process smell and taste, including the hypothalamus, amygdala, and insula. Because these drugs enter and act on the nervous system, they can alter how the brain interprets these signals.

GLP-1 is also produced naturally by some types of taste bud cells, so the medication could directly interact with the chemical messaging happening on the tongue.

While smell and taste disturbances are frequently linked to diabetic nerve damage, the researchers noted that recent case reports hint that the medications themselves could be playing a role, with symptoms resolving after discontinuing GLP-1 medications.

What Doctors Recommend

Outside experts who reviewed the study offered a mixed but largely reassuring take.

“Although the findings of this study can serve as a call to action to investigate further sensory complaints related to GLP-1 receptor agonist use, they provide no reason to believe that these therapies are unsafe,” Dr. Shernell Surratt-Gary, an osteopathic physician and graduate of Oklahoma State University Center for Health Sciences, told The Epoch Times.

The study relied on retrospective data and did not account for dosing levels or adherence to treatment. The researchers also used diagnostic billing codes rather than standardized smell and taste testing, a method that depends on patients noticing and reporting symptoms to their doctor in the first place.

Given the findings, the study’s authors say clinicians should discuss potential sensory side effects before prescribing GLP-1 drugs, including asking patients about their baseline sense of smell and taste, and considering testing tools for high-risk people. Patients who develop new or worsening symptoms should be evaluated by an ear, nose, and throat (ENT) specialist, the authors advise.

Dr. Fernando Ovalle Jr., a double board-certified plastic surgeon and obesity medicine specialist, an expert contributor for Drugwatch.com, who was not involved in the study, cautioned against assuming the drug is automatically to blame. “I would not automatically assume it is from the GLP-1,” he told The Epoch Times, noting that smell and taste changes can come from viral infections, sinus issues, dental problems, reflux, COVID-19, diabetes itself, neurologic conditions, or other medications.

Ovalle said he would ask patients about timing and whether the symptoms began after starting the GLP-1 or after a dose increase, and whether the symptoms are affecting nutrition, hydration, and quality of life.

“If it is mild, I would document it and monitor,” he said. “If it is persistent, worsening, or interfering with eating, I would consider adjusting the dose, temporarily holding the medication, or referring [the patient] to [an] ENT.”